DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study

  1. Michael Di Iorio
  2. Claire E. Cook
  3. Kathleen M.M. Vanni
  4. Naomi J. Patel
  5. Kristin M. D'Silva
  6. Xiaoqing Fu
  7. Jiaqi Wang
  8. Lauren C. Prisco
  9. Emily Kowalski
  10. Alessandra Zaccardelli
  11. Lily W. Martin
  12. Grace Qian
  13. Tiffany Y-T. Hsu
  14. Zachary S. Wallace
  15. Jeffrey A. Sparks

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.semarthrit.2022.152025
  2. ScreenIT

    SciScore for 10.1101/2022.02.08.22270696: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study was approved by the Mass General Brigham Institutional Review Board.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Study population: We systematically identified all SARD participants with SARS-CoV-2 confirmed by PCR, nucleocapsid antibody, or antigen testing (from March 1, 2020 to November 3, 2021 for this analysis) at Mass General Brigham (MGB) HealthCare system in the greater Boston, Massachusetts area, as previously described(2, 9, 11-14).
    antigen testing (from March 1
    suggested: None
    neutralizing monoclonal antibodies to SARS-CoV-2, or clinical trial enrollment), hospitalization, supplemental oxygen, and mechanical ventilation were obtained by survey.
    SARS-CoV-2
    suggested: None
    Software and Algorithms
    SentencesResources
    Study population: We systematically identified all SARD participants with SARS-CoV-2 confirmed by PCR, nucleocapsid antibody, or antigen testing (from March 1, 2020 to November 3, 2021 for this analysis) at Mass General Brigham (MGB) HealthCare system in the greater Boston, Massachusetts area, as previously described(2, 9, 11-14).
    SARS-CoV-2
    suggested: (Active Motif Cat# 91351, RRID:AB_2847848)
    Prolonged symptom duration definition: As in general population studies, prolonged symptom duration (or PASC) was defined either as those suffering from COVID-19 symptoms persistently for 28 or more days, or those whose symptoms initially resolved (or were not initially present) but then recurred/developed 28 or more days after COVID-19 onset, as defined by the US Centers for Disease Control and Prevention (CDC)(22, 23).
    PASC
    suggested: (PASC , RRID:SCR_016642)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study does have limitations. The cross-sectional nature allowed for the surveying of respondents at only one point in time post-COVID-19, possibly introducing recall bias, particularly related to assessment of disease activity and symptoms at acute COVID-19 onset. The survey response rate was 26%, similar to other survey studies, but there were some factors that may have response rate and could affect generalizability. We were also only able to assess survivors of COVID-19. Some participants who were very ill during their acute COVID-19 course may have been less likely to respond to the survey while recuperating. We found that hospitalization was significantly associated with prolonged symptom duration. Future studies may focus on this vulnerable population at high risk for protracted COVID-19 course. Our sample was heterogeneous, composed of participants with a variety of different SARDs. Future analyses in this study will focus on specific SARDs such as RA once the sample size is sufficient. Disease activity and flare were obtained by participant report rather than in-person physical examination. Since many SARD types were included, a single validated assessment would have been difficult to measure. However, the RAPID3 is commonly used as a survey instrument for all SARD participants to measure participant-reported disease activity and pain. It is possible that a small proportion of participants may have had persistent viral infection, as has been described for SARDs wi...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.02.08.22270696v1 on medRxiv